Hims & Hers Health (NYSE:HIMS) CFO Sells $79,420.50 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 3,975 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $19.98, for a total value of $79,420.50. Following the sale, the chief financial officer directly owned 318,789 shares of the company’s stock, valued at $6,369,404.22. The trade was a 1.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.77, for a total value of $219,088.09.
• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.34, for a total value of $275,092.78.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded down $0.79 during trading hours on Tuesday, reaching $19.54. The stock had a trading volume of 20,834,213 shares, compared to its average volume of 33,518,930. The business’s fifty day moving average is $20.47 and its two-hundred day moving average is $34.29. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The company has a market cap of $4.45 billion, a price-to-earnings ratio of 38.31, a PEG ratio of 2.31 and a beta of 2.32. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. The firm had revenue of $617.82 million during the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.11 earnings per share. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently made changes to their positions in the business. Hsbc Holdings PLC raised its stake in Hims & Hers Health by 427.1% during the 4th quarter. Hsbc Holdings PLC now owns 33,582 shares of the company’s stock worth $1,090,000 after buying an additional 27,211 shares during the period. Rockefeller Capital Management L.P. increased its position in shares of Hims & Hers Health by 13.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 41,088 shares of the company’s stock valued at $1,334,000 after acquiring an additional 4,980 shares during the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in shares of Hims & Hers Health during the fourth quarter valued at approximately $80,000. SHP Wealth Management purchased a new stake in shares of Hims & Hers Health during the fourth quarter valued at approximately $106,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Hims & Hers Health by 413.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 17,228 shares of the company’s stock valued at $559,000 after purchasing an additional 13,873 shares during the period. Institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on HIMS. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Citigroup upgraded Hims & Hers Health from a “sell” rating to a “neutral” rating and raised their price target for the company from $13.25 to $24.00 in a research note on Tuesday, March 10th. Truist Financial reiterated a “hold” rating and set a $18.00 target price (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. BTIG Research downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday, February 24th. Finally, Barclays boosted their price target on Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Three analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $31.71.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.